Sunday, 4 July 2021

What Do We Know About Covid-19

Although we only became aware of Covid-19 (SARS-Cov-2) in early 2020, scientists and researchers have now traced back to its early origins. 

Coronaviruses are widespread among many different mammals. SARS-Cov-1 came to humans from the Asian civet. Middle Eastern Respiratory Syndrome (MERS) came via dromedary camels. Covid-19 came directly from horseshoe bats.

Around the world, scientists have been studying coronaviruses for some years, in order to better understand how they function and how to develop vaccines against them. To do this they deliberately try to make existing microbes more infectious or deadly. This 'gain-of-function' research is used to work out well before it happens in nature (a) which viruses are likely to cause pandemics and (b) develop ways to stop this happening. 

While no serious scientist is claiming that such an engineered virus has been deliberately released, some are concerned that there may have been an accidental release. They note that the Covid-19 virus has multiple odd characteristics which make it well adapted to humans, while poorly adapted to bats, which are thought to be the original host species. Other scientists feel a natural origin is much more likely, and the 'lab leak' theory underestimates the power of natural selection.

Whichever of these views is correct we may never know. However to avoid the risks for future, serious bio-leaks, it is important that these labs operate with open scrutiny and accountability.

When did the virus first infect people?

In 2012, six mine workers in China had Covid-like symptoms after visiting a bat cave, but it seems no reports identified the cause.

2019 Nov.: Three researchers from the Wuhan laboratory fell ill around the time the pandemic appears to have begun.

In many countries, including the UK, the variety of virus mutations identified during early sampling was almost as great as the variety seen across the whole world. This suggests that the virus entered the UK many times independently, rather than via any one 'patient zero' case that seeded the UK national epidemic.

2019 Dec. 31: Chinese authorities notified the World Health Organisation (WHO) of a new and dangerous viral form of pneumonia recently found in Wuhan. At this point it had no name.

2020 Jan. 13: UK health bodies notified GP practices describing the new virus. As there were only three flights from Wuhan to the UK each week, the likely impact was estimated to be Very Low. 

2020 Jan. 20: With rapidly rising infections , the Chinese Health Commission confirmed it could spread between humans. At this time the Lunar Holiday season meant around 2 billion trips were made by people visiting families. On the 24th, train and plane journeys were cancelled to and from Wuhan. The process of lockdown had begun.

2020 Jan. 29: First confirmed cases in the UK were a Chinese couple staying in York. UK health bodies started to advise travellers from Wuhan to the UK to self-isolate for fourteen days, even if they had no symptoms.

2020 Feb. 5: WHO confirms there is no known effective treatment. It was becoming obvious that the virus was spreading rapidly, with many people showing no symptoms, which made isolating affected people more difficult. Later in Feb., France, Italy and Spain all reported cases, including within country infection.

2020 Mar. Many people returning to the UK from skiing holidays were coming down with coughs and fevers. Limited testing masked the true infection rate. Mar. 5. First UK death. Mar. 17: People advised to avoid going out, and self-isolate if anyone in a household had symptoms. Mar. 18: Schools closed.

SARS-Cov-2 now designated a pandemic by WHO.

2020 Apr. Now clear that for most people the virus irritates the upper airway, producing a dry cough, loss of taste and smell, and fever. Many have headaches, while for a few, the virus attacks the digestive tract. Four out of five start to recover after 4 or 5 days. In the rest (mostly middle-aged or over, overweight and male) , the virus attacks the lung tissue and treatment was limited.

2021 June. Now the most commonly reported symptoms are a cough, headache and fatigue. It is likely that this is due to the virus infecting younger and healthier people who have strong immune systems. But given the rate of spread of the Delta variant, it's possible many people believe they have a cold or hay fever, potentially putting others at risk of infection.

Herd immunity: The Delta variant is far more infectious than previous variants, so a higher rate of population immunity (85%) is needed to stop it spreading. This cannot be achieved by only vaccinating the adult population, and at least some of the under-18s will need to be vaccinated.

Impact on NHS: June 2021 Covid infections are at the same level at mid-December 2020, when hospitals were overwhelmed with severe cases and many deaths, but far fewer people now need hospital treatment and very few die, since the majority of current cases are in younger groups who have less risk of getting seriously ill. If more elderly people get infected, hospital cases (and deaths) will rise. 

Long Covid June 2021: Office of National Statistics survey show more than one million Britons are currently suffering from long Covid, with two-thirds of these having symptoms that impact on daily life. Early studies suggest that vaccines cut the risk of long Covid by around 50 per cent.

ACE-2 cells: Identified that Covid-19 binds frighteningly well to ACE-2 cells, which help regulate blood flow through body tissues. Men have more ACE-2 coating their cells, and children much less. This partly explains the pattern of (especially older) men often suffering more severe infections and children having minimal symptoms. Other factors such as poor housing, multi-generational living, and working in high contact jobs (care home assistants, cleaners and porters in hospitals) prior to wearing protective clothing are likely to account for the black, Asian and other ethnic minorities suffering more severely. 

Community lockdowns were effective in slowing transmission, and therefore reducing hospitalisations and deaths. But we don't see immediate benefits as some people are already infected (and passing the virus on to others) before they show symptoms. 

Main source:  Intensive Care: a GP, a Community & Covid-19 by Gavin Francis, Profile Books, 2021.

Sunday, 27 June 2021

Possible New Drug to Treat Alzheimer's Disease

 A drug appears to slow progression of Alzheimer's disease. Alzheimer's and other forms of dementia affect more than 40 million people world wide; a number which is estimated to rise to 75.6 million in 2030 as the world population continues to age.

Existing drugs only address symptoms while the disease continued to worsen. By contrast, an experimental drug - solanezumab - tackles beta amyloid, the toxic protein that destroys vital connections between brain cells. Beta amyloid is believed to build up in the brain for 10 or 15 years and steadily kills neurons before Alzheimer's symptoms appear.

Early trials were disappointing, but close analysis suggested there were some benefits if taken at a very early stage of the disease. Patients with mild symptoms who continued taking the drug for another two years preserved more of their cognitive and functional ability. Results suggest that the drug could slow cognitive decline by around 30%.

Details of the full risks and benefits of this drug must wait till ongoing trials finish in 18 months time (Dec. 2022?). The drug does have some side effects (which were not reported in the article).

Clinical findings about another drug (aduncanumab) also trialled in people with early stage Alzheimer's disease, were also presented. Interim results of a safety study found the drug reduced the amount of amyloid plaques in the brain, with an increasing effect as the dose increases. But more than a quarter of those on higher dose experienced headaches and between a third and a half showed abnormalities on a brain scan.

Source: New Drug to Tackle Alzheimer's disease in Daily Mail, 29 May 2021


Sunday, 20 June 2021

Mattel Launches Toy Send-back Scheme

 Mattel (which makes Barbie dolls and other plastic toys) has launched a send-back service. Parents can return children's unwanted toys to the company, so they can be recycled and re-used instead of going to landfill. 

Mattel Playback will be available in several countries, including the UK. Initially only Barbie, Matchbox and Mega construction toys will be accepted. The scheme will later be expanded to include other product lines. However it will not accept electronic goods or toys made by other manufacturers. 

Material from old Mattel dolls and building bricks will be recovered and used in new products.

Families who want to use this scheme can visit Mattel's PlayBack webpage and fill out their contact details and the product type they are sending back. They will then get an email with a link to a pre-paid shipping label to print out and attach to their package of items, which they can arrange to be collected.

Source: The I newspaper, 18th May 2021 Barbie manufacturer Mattel launches plastic toy send-back service.

Sunday, 13 June 2021

Covid-19 Vaccine Blood Clot Problem

 Warning: This has not been published in a per-reviewed journal, and this theory has not been independently replicated.

The vaccines made by AstraZeneca and Johnson & Johnson are being linked to a very rare blood clotting disorder. German scientists think they have worked out why, and potentially how to stop it.

Why is this important? Well, several countries have halted the rollout of the AstraZeneca vaccine, and recently Belgium announced it would stop using the J&J vaccine to those under 41. Avoiding just a few cases of blood clots is disrupting vaccination programmes for thousands of people for whom it would not be a problem.

Why do some vaccines have this rare side-effect? A German study (not yet peer-reviewed) suggests that Covid-19 vaccines that use adenovirus vectors (cold viruses) send some of their payload into the nucleus of cells. When this happens, the cells can misread the instructions for making coronavirus proteins, potentially triggering blood clot disorders in a small number of recipients. 

How does this happen? After entering the cell nucleus, parts of the spike protein splice or split apart, creating mutant versions which are unable to bind to the cell membrane. The spike protein, which is found on the surface of the Covid-19 virus, helps the virus to enter other host cells. These mutant versions then enter the body and trigger the rare blood clots.

Why does this not happen with all Covid-19 vaccines? The process is different for mRNA vaccines, such as those made by Pfizer and Moderna, as in these the genetic material of the spike protein is sent directly to the cell fluid and does not enter the nucleus. Researchers think that those using adenovirus vectors could alter the sequence of the spike protein "to avoid unintended splice reactions and to increase the safety of these pharmaceutical products."

How often does this happen? It is important to know that the blood clotting disorder is an extremely rare occurrence in people receiving a coronavirus vaccine. Latest data indicates that out of the 30.8 million doses of the AstraZeneca vaccine given in the UK between 9 Dec. 2020 and 5 May 2021, there have been more than 260 cases of blood clotting disorder (thrombosis with thrombocytopenia). This is the equivalent of 10.9 cases per million doses. The vast majority were reported after the first dose, and only eight after the second dose.

Source: Daily Express, 27 May 2021: German scientists claim to have finally cracked the vaccine blood clot puzzle.

Sunday, 6 June 2021

Viruses Compete to Infect Us

Some viruses are known to compete in order to be the one that causes an infection. Research at University of Glasgow indicates that cold-causing rhinovirus trumps coronavirus. Benefits might be short-lived but rhinovirus is so widespread it could still help to suppress Covid.

Once a virus gets inside the cells in your nose, throat and lungs it can either allow in other viruses (which means that you end up with symptoms of both) or can prevent them entering.

Influenza is one of the most selfish viruses around, and nearly always infects alone.

Adenoviruses are more likely to allow another virus in. They are common viruses that cause a range of illnesses. They can cause cold-like symptoms, fever, sore throat, bronchitis, pneumonia, diarrhoea and pink eye (conjunctivitis).

Rhinovirus severely inhibits Coronavirus infection by triggering an immune response inside infected cells, blocking the ability of Covid to make copies of itself. So a high prevalence of rhinovirus in the population could stop new Covid infections. But Covid would be able to cause an infection again once the cold had passed and the immune response calmed down. Rhinoviruses are the most common cause of the common cold. A large rhinovirus infection may have delayed the 2009 swine flu pandemic in parts of Europe. 

Source: Coronavirus: how the common cold can boot out Covid. BBC News item 23 March 2021 https://www.bbc.co.uk/news/health-56483445